Investor Relations
-
Message from the Chairman and CEO
We are working to meet the expectations of our shareholders and investors by enhancing corporate value.
-
Business Results for the First Six Months of the Fiscal Year Ending March 31, 2021
IR Information
-
-
Sysmex Obtains Manufacturing and Marketing Approval for a SARS-CoV-2 Antigen Detection Reagent
- Detecting SARS-CoV-2 Antigens Using Fully Automated Immunoassay Systems HISCL™-5000 / HISCL™-800 - (PDF：170KB) -
-
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
- The Content Presented at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference - (PDF：182KB) -
- Summary of Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2021 (PDF：438KB)
-
- Posted Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2021
-
- Sysmex Announces Financial Forecast for the Fiscal Year Ending March 31, 2021 (PDF：83KB)
